Connect with us

Technology

Cerebral And Tissue Oximetry Devices Market size is set to grow by USD 96.3 million from 2024-2028, Growing use of cerebral and tissue oximetry devices in cardiac surgical procedures boost the market, AI Role and Impact, Technavio

Published

on

NEW YORK, Aug. 22, 2024 /PRNewswire/ — The global cerebral and tissue oximetry devices market size is estimated to grow by USD 96.3 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  8.08%  during the forecast period. Growing use of cerebral and tissue oximetry devices in cardiac surgical procedures is driving market growth, with a trend towards technological advances in cerebral and tissue oximetry devices. However, high cost of cerebral and tissue oximetry devices  poses a challenge. Key market players include Artinis Medical Systems, Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies Inc., Hamamatsu Photonics KK, HyperMed Imaging Inc., ISS Inc., Masimo Corp., Medtronic Plc, Moor Instruments Ltd., Nonin Medical Inc., Sotera Health Co., Spectros Medical Devices Inc., Terumo Corp., and ViOptix Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Cerebral And Tissue Oximetry Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 8.08%

Market growth 2024-2028

USD 96.3 million

Market structure

Concentrated

YoY growth 2022-2023 (%)

7.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key countries

US, China, Germany, France, and Japan

Key companies profiled

Artinis Medical Systems, Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies Inc., Hamamatsu Photonics KK, HyperMed Imaging Inc., ISS Inc., Masimo Corp., Medtronic Plc, Moor Instruments Ltd., Nonin Medical Inc., Sotera Health Co., Spectros Medical Devices Inc., Terumo Corp., and ViOptix Inc.

Market Driver

The cerebral and tissue oximetry devices market is witnessing significant advancements, driven by vendors’ focus on offering innovative products with enhanced features and benefits. Technological progressions, such as the adoption of diffuse correlation spectroscopy (DCS) technology for sensitive and rapid blood flow measurements and cerebral metabolism ratio of oxygen in deeply located tissues, are key factors fueling market growth. Vendors are also integrating continuous-wave light sources instead of pulsed laser and frequency-modulated approaches to reduce costs. Notable technology offerings include Medtronic’s INVOS TECHNOLOGY, which provides multi-sensor monitoring and real-time data on the balance of oxygen supply and demand using a 3:1 ratio of venous and arterial blood. Edward Lifesciences’ LASER-SIGHT optical technology increases the accuracy and reliability of cerebral and tissue oximetry devices by using five precise wavelengths of NIRS. Nonin Medical’s EQUANOX technology offers six channels for simultaneous monitoring of peripheral oxygen saturation (SpO2) and rSO2, along with dual detector and dual emitter sensors for enhanced accuracy. These advancements in NIRS technologies are crucial for end-users seeking precise and accurate measurements for routine healthcare operations. The increasing adoption of cerebral and tissue oximetry devices is expected to significantly boost the growth of the global cerebral and tissue oximetry devices market during the forecast period. 

The Cerebral and Tissue Oximetry Devices market is witnessing significant growth due to the increasing focus on monitoring oxygen saturation levels in various medical settings. Minimally invasive procedures using portable cerebral oximeter monitors are becoming popular among physicians for measuring cerebral oxygenation levels in cerebral tissues. These devices use sensors, a cable, oximeter probe, and a light detector with a fiber-optic light source to measure oxygen levels in the brain. The geriatric population and those with neurodegenerative diseases are major users of these devices. Oxygen saturation monitoring is essential during surgeries, ICUs, research settings, neonatal care, and for premature infants. Sensor technologies and data analytics are trending in this market, enabling real-time monitoring and improved patient care. Cerebral oximetry devices are used to monitor oxygen saturation levels in muscles, liver, and other tissues, besides the brain. These devices are available as tabletop models and portable, handheld units, catering to diverse requirements in hospitals and other healthcare facilities. 

Explore a 360° Analysis of the Market: Unveil the Impact of AI. For complete insights- Request Sample!

Market Challenges

The cost is a crucial factor for end-users when purchasing cerebral and tissue oximetry devices. The expense related to components and overall system hardware, including monitors, sensors, mounting options, and maintenance, significantly influences their buying decision. Advanced technologies, such as Near Infrared Spectroscopy (NIRS), used in these devices for accurate blood oxygenation monitoring, increase the overall cost. Monitors range from USD12,000 to USD25,000, and mounting options like wall mounts and roll stands can cost up to USD1,000. Sensor costs vary, with adult sensors priced between USD50 and USD100, and pediatric/infant sensors costing USD100USD150. Maintenance costs, primarily battery replacements, range from USD450 to USD550. Large-scale hospitals and clinical settings can justify these investments, but small healthcare facilities face challenges justifying the costs, potentially hindering the adoption and growth of the global cerebral and tissue oximetry devices market.The Cerebral and Tissue Oximetry Devices market is witnessing significant growth due to the increasing demand for non-invasive monitoring of oxygen saturation levels in various medical settings. These devices use sensors to measure tissue oxygen levels in muscles, liver, and during surgeries in ICUs, research settings, neonatal care, and premature infants. Sensor technologies and data analytics play a crucial role in providing real-time data for surgical procedures in operating rooms and outpatient settings. However, high device costs and complex reimbursement policies pose challenges to market growth. User-friendly design, portability, and flexibility are essential features for end-users. Tabletop devices are common in hospitals, while handheld devices offer convenience for healthcare professionals in diverse medical specialties, including neurological conditions, cardiovascular disorders, and heart disease. AI integration, wireless connectivity, and data analysis capabilities are emerging trends, enabling home healthcare and mobile monitoring systems for chronic diseases like peripheral artery disease. Surgeons and healthcare professionals rely on these devices for real-time data during surgeries, enhancing patient safety and outcomes.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This cerebral and tissue oximetry devices market report extensively covers market segmentation by  

Product 1.1 Modular devices1.2 Handheld devicesEnd-user 2.1 Hospitals2.2 ClinicsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Modular devices-  Handheld cerebral and tissue oximetry devices are compact, next-generation tools that provide instantaneous oxygen level measurements in blood without requiring direct patient contact or external connections to sensors and monitors. Advanced compatibility features enable these devices to pair with modular offerings from vendors, creating comprehensive solutions for medical practitioners during pre-operative, intra-operative, and postoperative assessments. Paired devices allow for real-time monitoring and decision-making during surgeries, saving valuable time. Proprietary spectrometer technology, such as HyperMed Imaging’s HyperView and ViOptix’s Intra.Ox, sets handheld devices apart from standard-of-care diagnostic imaging tools, which cannot distinguish oxygenated and deoxygenated hemoglobin. This advantage, along with applications in vascular procedures, wound care, and reconstructive surgeries, is fueling market growth for handheld cerebral and tissue oximetry devices.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

Cerebral and tissue oximetry devices measure oxygen saturation levels in cerebral tissues, including muscles and the liver. These devices are essential in various settings such as surgeries in ICUs, research settings, neonatal care for premature infants, and outpatient settings. Surgical procedures and operating rooms particularly benefit from real-time monitoring of cerebral oxygenation levels to ensure optimal patient care. High device costs and complex reimbursement policies pose challenges to widespread adoption. Advancements in technology include AI integration and wireless connectivity, enabling seamless integration into medical specialties treating chronic diseases and neurological conditions. Physicians rely on cerebral oximeter monitors, which include a cable and oximeter probe, typically placed on the forehead area. The device utilizes a light detector and fiber-optic light source to assess oxygen saturation levels in cerebral tissues.

Market Research Overview

Cerebral and tissue oximetry devices are non-invasive tools used to measure oxygen saturation levels in various tissues, including muscles, liver, and cerebral tissues. These devices use sensors to detect the amount of oxygen in the tissue based on the amount of light absorbed. They are used in various settings such as surgeries, ICUs, research settings, neonatal care, and home healthcare. Premature infants and patients with chronic diseases, neurological conditions, and cardiovascular disorders benefit from these devices. Sensor technologies have advanced to include data analytics, AI integration, and wireless connectivity, making them user-friendly, portable, and flexible. Handheld devices and tabletop devices are popular due to their portability and real-time data capabilities. High device costs and reimbursement policies are challenges in the market. These devices are used in surgical procedures, operating rooms, outpatient settings, and minimally invasive procedures. Surgeons and healthcare professionals rely on cerebral oximeter monitors to monitor cerebral oxygenation levels in the brain, especially during cardiac surgeries and cardiovascular diseases. Geriatric population with neurodegenerative diseases also benefits from these devices. Oxygen saturation levels are essential indicators of tissue health, and these devices provide valuable information for medical specialties to make informed decisions.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductModular DevicesHandheld DevicesEnd-userHospitalsClinicsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerebral-and-tissue-oximetry-devices-market-size-is-set-to-grow-by-usd-96-3-million-from-2024-2028–growing-use-of-cerebral-and-tissue-oximetry-devices-in-cardiac-surgical-procedures-boost-the-market-ai-role-and-impact-technavio-302228668.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

XLCS Partners advises Concurrent Utility Services on sale to UniTek Global Services

Published

on

By

NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ — XLCS Partners, Inc., a leading middle market investment bank, is pleased to announce that it served as exclusive M&A advisor to Concurrent Utility Services LLC on its acquisition by UniTek Global Services, Inc., a portfolio company of New Mountain Finance Corporation (Nasdaq: NMFC) and its affiliates, and BTG Pactual Strategic Capital.

Headquartered in Miami, Florida, Concurrent is a licensed general and electrical contractor providing infrastructure development and maintenance services to electric utilities, telecom providers, and land developers throughout the Southeast United States. The company’s capabilities span overhead and underground utility construction, professional telecom services, emergency service restoration, in-building networks, environmental services, and data center development. Backed by a safety-first culture and an experienced workforce, Concurrent has built a strong regional platform and a reputation for quality across the markets it serves.

UniTek is a leading digital infrastructure services provider supporting the expansion of fiber and data center connectivity across the U.S. and Canada. With over 600 employees and 60 locations, UniTek delivers a full suite of infrastructure services. The acquisition of Concurrent accelerates UniTek’s Power Services Division, which launched in July 2025 to broaden the company’s maintenance, repair, upgrade, and new infrastructure development services for the power sector. Concurrent’s established Southeast footprint and power capabilities directly complement UniTek’s existing broadband and data center infrastructure platform, positioning the combined company to capitalize on growing demand for resilient, modernized power infrastructure. Concurrent will continue to operate under its established brand, maintaining uninterrupted service for its customers.

“Selling Concurrent was one of the biggest decisions of my career, and Anthony, Jay, and the XLCS team guided us through every step with professionalism and genuine care for our people,” said Steve Sarno, CEO of Concurrent. “They stayed fully engaged throughout, gave us honest and thoughtful advice, kept our best interests front and center, and delivered an outcome that exceeded our expectations. I would recommend them without hesitation to any owner considering a transaction.”

XLCS acted as the exclusive M&A advisor to Concurrent, and the transaction was led by Anthony Contaldo, Partner, and Jay Cremer, Vice President. The transaction was completed on July 1, 2026.

About XLCS Partners, Inc.

XLCS Partners is a leading global investment banking firm providing M&A advisory services. Visit www.xlcspartners.com for more information.

Media Contact: 
Kendra Span 
kspan@xlcspartners.com
615-379-7783

View original content to download multimedia:https://www.prnewswire.com/news-releases/xlcs-partners-advises-concurrent-utility-services-on-sale-to-unitek-global-services-302833542.html

SOURCE XLCS Partners, Inc.

Continue Reading

Technology

XLCS Partners advises Concurrent Utility Services on sale to UniTek Global Services

Published

on

By

NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ — XLCS Partners, Inc., a leading middle market investment bank, is pleased to announce that it served as exclusive M&A advisor to Concurrent Utility Services LLC on its acquisition by UniTek Global Services, Inc., a portfolio company of New Mountain Finance Corporation (Nasdaq: NMFC) and its affiliates, and BTG Pactual Strategic Capital.

Headquartered in Miami, Florida, Concurrent is a licensed general and electrical contractor providing infrastructure development and maintenance services to electric utilities, telecom providers, and land developers throughout the Southeast United States. The company’s capabilities span overhead and underground utility construction, professional telecom services, emergency service restoration, in-building networks, environmental services, and data center development. Backed by a safety-first culture and an experienced workforce, Concurrent has built a strong regional platform and a reputation for quality across the markets it serves.

UniTek is a leading digital infrastructure services provider supporting the expansion of fiber and data center connectivity across the U.S. and Canada. With over 600 employees and 60 locations, UniTek delivers a full suite of infrastructure services. The acquisition of Concurrent accelerates UniTek’s Power Services Division, which launched in July 2025 to broaden the company’s maintenance, repair, upgrade, and new infrastructure development services for the power sector. Concurrent’s established Southeast footprint and power capabilities directly complement UniTek’s existing broadband and data center infrastructure platform, positioning the combined company to capitalize on growing demand for resilient, modernized power infrastructure. Concurrent will continue to operate under its established brand, maintaining uninterrupted service for its customers.

“Selling Concurrent was one of the biggest decisions of my career, and Anthony, Jay, and the XLCS team guided us through every step with professionalism and genuine care for our people,” said Steve Sarno, CEO of Concurrent. “They stayed fully engaged throughout, gave us honest and thoughtful advice, kept our best interests front and center, and delivered an outcome that exceeded our expectations. I would recommend them without hesitation to any owner considering a transaction.”

XLCS acted as the exclusive M&A advisor to Concurrent, and the transaction was led by Anthony Contaldo, Partner, and Jay Cremer, Vice President. The transaction was completed on July 1, 2026.

About XLCS Partners, Inc.

XLCS Partners is a leading global investment banking firm providing M&A advisory services. Visit www.xlcspartners.com for more information.

Media Contact: 
Kendra Span 
kspan@xlcspartners.com
615-379-7783

View original content to download multimedia:https://www.prnewswire.com/news-releases/xlcs-partners-advises-concurrent-utility-services-on-sale-to-unitek-global-services-302833542.html

SOURCE XLCS Partners, Inc.

Continue Reading

Technology

Fathom Applauds Introduction of the FRONTIER Act, the First Federal Blueprint for Independent AI Verification

Published

on

By

Reps. Lori Trahan (D-MA-03) and Jay Obernolte (R-CA-23) introduce a bill to build a competitive marketplace of independent verifiers for frontier AI models.

WASHINGTON, July 23, 2026 /PRNewswire/ — Fathom welcomes the introduction of the FRONTIER Act, the most complete federal framework yet for independent, third-party verification of frontier AI. The legislation is built to earn public trust as AI technology continues to accelerate. As frontier systems begin to take autonomous action in the world, the gap between what these models can do and our ability to keep them in check is widening. FRONTIER is the starting point to close that gap.

“AI governance keeps running into the same wall. The technology is hard to measure and it moves faster than any law can keep up with,” said Andrew Freedman, Co-Founder and CEO of Fathom. “Trying to write the perfect rules and freezing them in place won’t work. What will work is a competitive market of independent verifiers who are accountable for real-world outcomes and who the government can actually count on. The FRONTIER Act shows we can move fast and still get this right.”

The bill gets the fundamentals correct. It sets one public standard – the adequate mitigation of catastrophic risk – and holds both the AI companies and their independent verifiers accountable to it. FRONTIER does not freeze a single testing method into statute. Instead, it licenses competing verification organizations, allows them to sharpen their methods, and gives the government the power to revoke a license when a verifier’s work does not hold up in the field. That is how you build a system that keeps pace with the science instead of falling behind it.

Fathom thanks Reps. Trahan and Obernolte for their leadership, and for their courage in releasing a discussion draft, inviting scrutiny, and incorporating substantive improvements from across the field. One priority improvement as the bill advances: giving the government a fuller range of tools to act upstream – for pushing companies to close identified gaps in risk mitigation early, rather than only once a catastrophe is imminent. We are committed to working with these sponsors, committees of jurisdiction, and Congressional leadership to continue refining the bill in the weeks and months ahead.

About Fathom
Fathom is an independent nonprofit whose mission is to build a governance architecture that helps society navigate the transition to a world with AI by fostering trust, safety, and innovation. Fathom has developed and championed the independent verification model for AI and works with policymakers across the country to put it into practice. Learn more at http://fathom.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fathom-applauds-introduction-of-the-frontier-act-the-first-federal-blueprint-for-independent-ai-verification-302833546.html

SOURCE Fathom AI Inc.

Continue Reading

Trending